Contrast-induced nephropathy (CIN) is the third leading cause of acquired acute renal injury in hospitalized patients. Alprostadil plays a role in the maintenance and redistribution of intrarenal blood flow and the excretion of electrolytes and water. However, the effectiveness of alprostadil in preventing CIN remains controversial. Thirty-six articles with a total of 5495 patients were included in this study. Both groups (experimental group and control group) received standard hydration therapy. In the experimental group, patients received different doses of alprostadil. Serum creatinine (SCr), blood urea nitrogen (BUN), estimated glomerular filtration rate (eGFR), cystatin C, creatinine clearance rate (CCr), and β2-microglobulin (β2-MG) were measured at 24, 48, and 72 hours after contrast media injection. The incidence of CIN in the experimental group was significantly lower than that in the control group (6.56% vs 16.74%). The level of SCr, cystatin C, BUN, and β2-MG in the experimental group was lower than those in the control group; CCr and eGFR in the experimental group were higher than those in the control group. This study demonstrated that alprostadil may reduce the incidence of CIN in patients undergoing coronary angiogram and/or percutaneous coronary intervention.
LiebetraCGaedeLDoerrO. Neutrophil gelatinase-associated lipocalin (NGAL) for the early detection of contrast-induced nephropathy after percutaneous coronary intervention. Scand J Clin Lab Invest. 2014;74(2):81–8.
2.
SaritemurMTurkeliMKalkanKTanbogaİHAksakalE. Relation of uric acid and contrast-induced nephropathy in patients undergoing primary percutaneous coronary intervention in the ED. Am J Emerg Med. 2014;32(2):119–23.
3.
NashKHafeezAHouS. Hospital-acquired renal insufficiency. Am J Kidney Dis. 2002;39(5):930–6.
4.
KoYGLeeBKKangWC. Preventive effect of pretreatment with intravenous nicorandil on contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography (PRINCIPLE Study). Yonsei Med J. 2013;54(4):957–64.
5.
FanYWeiQCaiJ. Preventive effect of oral nicorandil on contrast-induced nephropathy in patients with renal insufficiency undergoing elective cardiac catheterization. Heart Vessels. 2016;31(11):1776–82.
6.
MehranR. Contrast-induced nephropathy remains a serious complication of PCI. J Interv Cardiol. 2007;20(3):236–40.
7.
AurelioADuranteA. Contrast-induced nephropathy in percutaneous coronary interventions: pathogenesis, risk factors, outcome, prevention and treatment. Cardiology. 2014;128(1):62–72.
8.
AndreucciMFagaTPisaniASabbatiniMRussoDMichaelA. Prevention of contrast-induced nephropathy through a knowledge of its pathogenesis and risk factors. Scientific World J. 2014;2014:823169.
9.
VercellinoMBezanteGPBalbiM. Contrast medium induced nephropathy: new insights into prevention and risk management. Cardiovasc Hematol Agents Med Chem. 2009;7(2):166–80.
10.
ThomsenHSMorcosSKAlmenT. Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol. 2013;23(2):307–18.
PattiGRicottiniENuscaA. Short-term, high-dose atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [Atorvastatin for Reduction of Myocardial Damage during Angioplasty–Contrast-Induced Nephropathy] trial. Am J Cardiol. 2011;108(1):1–7.
13.
KayaAKurtMTanbogaIH. Rosuvastatin versus atorvastatin to prevent contrast induced nephropathy in patients undergoing primary percutaneous coronary intervention (ROSA-cIN trial). Acta Cardiol. 2013;68(5):489–94.
14.
KiskiDStepperWBreithardtGReineckeH. Impact of female gender on frequency of contrast medium-induced nephropathy: post hoc analysis of dialysis versus diuresis trial. J Womens Health (Larchmt). 2010;19(7):1363–8.
15.
WeisbergLSKurnikPBKurnikBR. Dopamine and renal blood flow in radiocontrast-induced nephropathy in humans. Ren Fail. 1993;15(1):61–8.
16.
YaoKHeyneNErleyCMRislerTOsswaldH. The selective adenosine A1 receptor antagonist KW-3902 prevents radiocontrast media-induced nephropathy in rats with chronic nitric oxide deficiency. Eur J Pharmacol. 2001;414(1):99–104.
17.
ChoiJLeeHChangD. Effect of dopamine on excretory urographic image quality and the prevention of contrast-induced nephropathy in dogs. J Vet Med Sci. 2001;63(4):383–8.
18.
MajumdarSRKjellstrandCMTymchakWJHervas-MaloMTaylorDATeoKK. Forced euvolemic diuresis with mannitol and furosemide for prevention of contrast-induced nephropathy in patients with CKD undergoing coronary angiography: a randomized controlled trial. Am J Kidney Dis. 2009;54(4):602–9.
19.
ChenHH. Atrial natriuretic peptide for the prevention of contrast-induced nephropathy: what’s old is new but at the right dose and duration of therapy. J Am Coll Cardiol. 2009;53(12):1047–9.
20.
MorikawaSSoneTTsuboiH. Renal protective effects and the prevention of contrast-induced nephropathy by atrial natriuretic peptide. J Am Coll Cardiol. 2009;53(12):1040–6.
21.
OguzhanNCilanHSipahiogluM. The lack of benefit of a combination of an angiotensin receptor blocker and calcium channel blocker on contrast-induced nephropathy in patients with chronic kidney disease. Ren Fail. 2013;35(4):434–9.
22.
ZhanBMPanXSunWH. The effect of alprostadil on the prevention of contrast-induced nephropathy in patients undertaking coronary angiography: a meta-analysis. J Evid-Based Med. 2015;15:161–7.
23.
YeZLuHGuoW. The effect of alprostadil on preventing contrast-induced nephropathy for percutaneous coronary intervention in diabetic patients: a systematic review and meta-analysis. Medicine. 2016;95(46):e5306.
24.
XiaoL. Preventive effect of alprostadil in contrast induced nephropathy of patients with coronary heart disease and diabetes mellitus underwent percutaneous coronary intervention surgery. Chin J Clin Rational Drug Use. 2017;10:1–2.
25.
LiangMYangSCFuNK. Efficacy of alprostadil in preventing contrast-induced nephropathy in patients undergoing percutaneous coronary intervention: a multicenter prospective randomized controlled trial. Catheter Cardiovasc Interv. 2018;91(4):742–50.
26.
LiWHLiDYQianWH. Prevention of contrast-induced nephropathy with prostaglandin E1 in high-risk patients undergoing percutaneous coronary intervention. Int Urol Nephrol. 2014;46(4):781–6.
27.
MiaoYZhongYYanHLiWWangBYJinJ. Alprostadil plays a protective role in contrast-induced nephropathy in the elderly. Int Urol Nephrol. 2013;45(4):1179–85.
28.
YangSCFuNKZhangJ. Preventive effects of alprostadil against contrast-induced nephropathy inpatients with renal insufficiency undergoing percutaneous coronary intervention. Angiology. 2018;69(5):393–9.
29.
FranzRWHinzeSSKnappEDJenkinsJJ2nd. Oral prostaglandin E1 in combination with sodium bicarbonate and normal saline in the prevention of contrast-induced nephropathy: a pilot study. Int J Angiol. 2011;20(4):229–34.
30.
SpargiasKAdreanidesEDemeroutiE. Iloprost prevents contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation. 2009;120(18):1793–9.
31.
WangJAiXBLiL. Alprostadil protects type 2 diabetes mellitus patients treated with metformin from contrast-induced nephropathy. Int Urol Nephrol. 2017;49(11):2019–26.
32.
SketchMHJrWheltonASchollmayerE. Prevention of contrast media-induced renal dysfunction with prostaglandin E1: a randomized, double-blind, placebo-controlled study. Am J Ther. 2001;8(3):155–62.
33.
KochJAPlumJGrabenseeBModderU. Prostaglandin E1: a new agent for the prevention of renal dysfunction in high risk patients caused by radiocontrast media? PGE1 Study Group. Nephrol Dial Transplant. 2000;15(1):43–9.
34.
CaiQH. Efficacy of hydration and alprostadil prevention of coronary heart disease in elderly patients with coronary angiography after contrast-induced nephropathy (CAN). Mod Diagn Treat. 2014;22:5052–3.
35.
DongJCLiDZLinJHeSLWangBY. Inhibitory effect of intravenous hydration combined with alprostadil on contrast-induced nephropathy in patients with percutaneous coronary intervention. China Pharm. 2013;24:1870–2.
36.
FangMC. Research on preventive effect of alprostadil in interventional therapy on the radiographic contrast nephropathy of patients with diabetes and coronary heart disease. Diabetes N World. 2017;15:23–4.
37.
LeiJYChangHXLiaoSDMaF. Preventive effect of alprostadil combining hydration therapy on contrast-induced nephropathy after percutaneous coronary intervention in elder patients. Chin Circulat J. 2015;30:841–4.
38.
LiBBaiBXLiXl. Effect of alprostadil on contrast-induced nephropathy in senile patients after percutaneous coronary intervention. Chin J Geriatr Heart Brain Vessel Dis. 2011;13:344–6.
39.
LiJZZhangJYZhangL. Research of prostaglandin E1 and vitamin C in the prevention of contrast induced nephropathy. Chin J Pract Med. 2016;43:9–11.
40.
LiJR. Effect of prophylactic use of alprostadil on contrast-induced nephropathy in patients with coronary heart disease and diabetes. World Latest Med Inform (Electronic Version). 2016;16:114–5.
41.
LiYNYangSCFuNK. Role of prostaglandin E1 in prevention of contrast-induced nephropathy in elderly CHD patients undergoing PCI. Chin J Geriatr Heart Brain Vessel Dis. 2014;16:580–3.
42.
LiuCLiQLiuY. A clinical study of alprostadil combined with atorvastatin on prevention of contrast agent induced acute kidney injury in diabetic nephropathy patients. J Med Res. 2017;46:76–9.
43.
LiuYLongJJFuQ. Effects of lipo-PGE1 on prophylaxis of radiocontrast-induced nephropathy and hemorrheology in patients with coronary heart disease. Chin J Hemorh. 2011;21:597–9.
44.
MeiBQYangXLXuZY. Effects of alprostadil on oxidative stress in contrast-induced nephropathy in patients with chronic kidney disease. J Pract Radiol. 2018;34:274–7.
45.
MuJL. Preventive effect of alprostadil on contrast-induced nephropathy in patients with coronary heart disease complicated with diabetes undergoing percutaneous coronary intervention. Doctor. 2017;2:3–4.
46.
SunXXWangALZuoHQinLM. Preventive effect of alprostadil on contrast-induced nephropathy in patients with coronary heart disease complicating diabetes undergone percutaneous coronary intervention. Chin J Evid Based Cardiovasc Med. 2015;7:647–9.
47.
WangJPengYPGongJB. Effect of alprostadil on contrast-induced nephropathy in coronary heart disease patients with type 2 diabetes undergoing percutaneous coronary intervention. Military Med J Southeast China. 2014;16:28–30.
48.
WuYHeYHuangWH. The preventive effect of alprostadil lipo preparation on contrast induced nephropathy in patients with PCI. Chin J Diffic Compl Cas. 2016;15:154–7.
49.
XiongNPengZQLiuJ. Efficacy of alprostadil injection on prophylaxis of contrast-induced nephropathy. Chin J Intervent Cardiol. 2014;22:89–91.
50.
XuRXiaJDJinCL. Effect of alprostadil injection on contrast-induced nephropathy in patients with heart failure after coronary intervention. J Clin Res. 2012;29:1128–30.
51.
YanHYChenSQYangDP. Clinic observation of the effects of alprostadil jointed hydration on preventing contrast introduced nephropathy in elderly patients with renal insufficiency. J Clin Nephrol. 2014;14:547–50.
52.
YangXJKongLCLiuSY. Study on the preventive effect of alprostadil on contrast induced nephropathy in interventional therapy for diabetic patients with coronary heart disease. J Clin Exper Med. 2018;17:284–6.
53.
YangZYShaoYGuoNP. Renal protection effect of alprostadil microspheres in patients with moderate renal function decline undergoing percutaneous coronary intervention. J China-Japan Friendship Hosp. 2014;28:277–9.
54.
YaoDNYangXC. Observation on efficacy of alprostadil combined with intravenous hydration in prevention of contrast-induced nephropathy after percutaneous coronary intervention in patients with coronary heart disease and type 2 diabetes mellitus. Evaluat Anal Drug-Use Hosp China. 2017;17:1226–7.
55.
YeYYangYHanZHLiuJ. Clinical evaluation of lipo-PGEl on prophylaxis of radiocontrast-induced nephropathy in elder patients. Chin J N Drugs. 2006;15:1386–9.
56.
ZhangY. The Study of Alprostadil in Prevention of Contrast Induced Nephropathy in Diabetic Patients After Percutaneous Coronary Intervention[Dissertation]. Kunming, China: Kunming Medical University; 2014.
57.
ZhaoHW. Effects of combination therapy of hemoperfusion and alprostadil on early contrast-induced nephropathy in patients with coronary heart disease and type 2 diabetes after percutaneous coronary intervention. Med Innov China. 2014;11:33–5.
58.
ZhongSGYangFChenAW. The preventive effect of alprostadil on contrast nephropathy among the patients with coronary artery disease complicated with diabetes in the interventional therapy. Chin Gen Pract. 2014;17:3720–3.
59.
ZhouDCLuMLiZQ. Preventive effect of alprostadil on contrast-induced nephropathy in patients undergoing coronary intervention. Chin J Postgrad Med. 2013;36:34–6.
60.
ZhuLRuanZBYinYG. Preventive effect of prostaglandin E1 on contrast medium-induced nephropathy in patients with coronary disease combined with diabetes mellitus. Chin J Geriatr. 2011;30:830–2.
61.
MitchellAMKlineJA. Contrast nephropathy following computed tomography angiography of the chest for pulmonary embolism in the emergency department. J Thromb Haemost. 2007;5(1):50–4.
62.
HossainMACostanzoECosentinoJ. Contrast-induced nephropathy: pathophysiology, risk factors, and prevention. Saudi J Kidney Dis Transpl. 2018;29(1):1–9.
63.
WongPCLiZGuoJZhangA. Pathophysiology of contrast-induced nephropathy. Int J Cardiol. 2012;158(2):186–92.
64.
RahmanMMHaqueHSBanerjeeSK. Contrast induced nephropathy in diabetic and non-diabetic patients during coronary angiogram and angioplasty. Mymensingh Med J. 2010;19(3):372–6.
65.
FishbaneS. N-acetylcysteine in the prevention of contrast-induced nephropathy. Clin J Am Soc Nephrol. 2008;27:281–7.
66.
AsifAPrestonRARothD. Radiocontrast-induced nephropathy. Am J Ther. 2015;92:137–47.
67.
ItohYYanoTSendoT. Involvement of de novo ceramide synthesis in radiocontrast-induced renal tubular cell injury. Kidney Int. 2006;69(2):288–97.
68.
HallerCHizohI. The cytotoxicity of iodinated radiocontrast agents on renal cells in vitro. Invest Radiol. 2004;39(3):149–54.
69.
TouyzRMBrionesAM. Reactive oxygen species and vascular biology: implications in human hypertension. Hypertens Res. 2011;34(1):5–14.
70.
GraboschSMShariffOMHelmCW. Non-steroidal anti-inflammatory agents to induce regression and prevent the progression of cervical intraepithelial neoplasia. Cochrane Database Syst Rev. 2018;(2):CD004121.
71.
SolomonRDerayG. How to prevent contrast-induced nephropathy and manage risk patients: practical recommendations. Kidney Int Suppl. 2006;69:51–3.
72.
OwenRJHiremathSMyersA. Canadian Association of Radiologists consensus guidelines for the prevention of contrast-induced nephropathy: update 2012. Can Assoc Radiol J. 2011;58:79–86.
